Speedus (CE) (USOTC:SPDE)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Speedus (CE) Charts. Click Here for more Speedus (CE) Charts.](/p.php?pid=staticchart&s=NO%5ESPDE&p=8&t=15)
Zargis Medical Receives FDA Clearance:
Energy Display and Timing Annotation Added to Cardioscan
PRINCETON, N.J., Sept. 14 /PRNewswire/ -- Zargis Medical Corp., a
majority-owned subsidiary of Speedus Corp. (NASDAQ:SPDE), announced today it
has received U.S. Food and Drug Administration (FDA) clearance to include a
graphical display of the median energy level, timing, and duration of suspected
heart murmurs during specific segments of the diastolic and systolic intervals
of heartbeats recorded through the Zargis Acoustic Cardioscan (Cardioscan(TM)).
The new displays will better represent the distribution of acoustic energy of
the heart for each recorded location and help physicians characterize suspected
murmurs in terms of onset, duration and loudness. This clearance represents
one of the planned development milestones required for a full commercial
rollout of Cardioscan.
Zargis will be demonstrating Cardioscan, with energy display and timing
annotation, at the American Heart Association Scientific Sessions in New
Orleans on November 7th - 10th.
"We have developed the most comprehensive and advanced heart sound analysis and
interpretation algorithms in the world. This FDA clearance represents another
first for Zargis and demonstrates our commitment to extending the clinical
usefulness of cardiac auscultation (listening to heart sounds). Because
auscultation is a difficult clinical skill, and with fewer than 28% of internal
medicine programs in the United States offering any structured teaching in
cardiac auscultation, we see a need for continued innovations in the field of
cardiac sound diagnostics," said John Kallassy, Managing Director of Zargis
Medical.
The acoustic signal generated by the heart contains significant energy at
frequencies below the threshold of human hearing. The decline in auscultation
skills has also led to a possible over-reliance on costly echocardiography for
the diagnosis of heart murmurs. Consequently, a large percentage of
echocardiograph studies are performed on patients with innocent heart murmurs.
About Cardioscan
Cardioscan is the first and only computer-aided medical device to support
physicians in analyzing heart sounds for the identification of suspected
murmurs, a potential sign of heart disease. Cardioscan is easy to use,
non-invasive, portable, and takes just minutes to perform. Developed by
biomedical scientists from Siemens and Zargis over the past seven years,
Cardioscan implements voice-guided protocol and graphical user interface while
maintaining an efficient physician workflow. The system provides a summary of
findings in terms that are readily understood by physicians with more
quantitative auscultatory information than is possible through listening alone.
Thus, Cardioscan enhances auscultation which has been universally employed
through a stethoscope for nearly two hundred years.
About Zargis Medical Corp.
Zargis Medical Corp. was formed in January 2001 when Siemens Corporate Research
Inc., a subsidiary of Siemens AG (NYSE:SI), and Speedus Corp. (NASDAQ:SPDE)
co-invested in Zargis to further develop and commercially market an advanced
acoustic technology for detecting abnormalities identified through analysis of
heart sounds. Based in Princeton, New Jersey, Zargis is developing advanced
diagnostic decision support products and services for primary care physicians,
cardiologists and other healthcare professionals.
For additional information on Speedus Corp. or Zargis Medical, contact John
Kallassy, 718.567.4358, , or visit their websites at http://www.speedus.com/
and http://www.zargis.com/.
For additional information on Siemens Corporate Research, visit their website
at http://www.scr.siemens.com/.
Statements contained herein that are not historical facts, including but not
limited to statements about the Company's product, corporate identity and
focus, may be forward-looking statements that are subject to a variety of risks
and uncertainties. There are a number of important factors that could cause
actual results to differ materially from those expressed in any forward-looking
statements made by the Company, including, but not limited to, the continuing
development of the Company's sales, marketing and support efforts.
DATASOURCE: Zargis Medical Corp.
CONTACT: John Kallassy, +1-718-567-4358,
Web site: http://www.speedus.com/
http://www.zargis.com/
http://www.scr.siemens.com/